The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
FDA: Amivantamab with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. EMA: Amivantamab in combination with carboplatin and pemetrexed for the first line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutationsPAPILLON
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+ exon 20 insertion mutations
PAPILLON
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Mirvetuximab soravtansine-gynx
-
Paclitaxel, pegylated liposomal doxorubicin, or topotecan. (Investigator’s choice of chemotherapy)
Mirvetuximab soravtansine-gynx for adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimensMIRASOL, Study 0416
Gynaecological Malignancies
Epithelial ovarian, fallopian tube or primary peritoneal cancer
FRalpha positive
MIRASOL, Study 0416
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Enzalutamide
-
Placebo + Leuprolide
As monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy EMBARK
Genitourinary Cancers
Prostate cancer
PSA doubling time ≤ 9 month
EMBARK
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Trastuzumab deruxtecan
-
Single arm
Trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment optionsDESTINY-Lung01
Thoracic Malignancies
Non-small-cell Lung Cancer
HER2 (IHC 3+)
DESTINY-Lung01
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Trastuzumab deruxtecan
-
Single arm
Trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment optionsDESTINY-PanTumor02
Breast Cancer
Tumor agnostic
HER2 (IHC 3+)
DESTINY-PanTumor02
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Alectnib
-
Platinum-Based ChT
Alectinib for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancerALINA
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK positive
ALINA
A
PRELIMINARY SCORE
DFS
ADJUSTMENTS
FINAL SCORE
F1
A
Nogapendekin alfa inbakicept
Bacillus Calmette-Guérin (BCG)
Single arm
Nogapendekin alfa inbakicept-pmln with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (Ta/T1; Cohort A)QUILT-3.032
Genitourinary Cancers
Urothelial Carcinoma (NMIBC)
BCG-unresponsive
QUILT-3.032
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Talazoparib
Enzalutamide
Placebo plus enzalutamide
Talazoparib with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).TALAPRO-2
Genitourinary Cancers
Prostate cancer
HRR gene-mutated
TALAPRO-2
3
PRELIMINARY SCORE
rPFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Repotrectinib
-
Single arm
Repotrectinib used for locally advanced or metastatic ROS1-positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive NSCLC who are TKI naïve.TRIDENT-1
Thoracic Malignancies
Non-small-cell Lung Cancer
ROS1-positive (TKI naïve)
TRIDENT-1
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Sugemalimab
Platinum-based chemotherapy
Placebo
Sugemalimab for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapyGEMSTONE-302
Thoracic Malignancies
Non-small-cell Lung Cancer
-
GEMSTONE-302
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Tarlatamab (10mg)
-
Single arm
Tarlatamab treatment for the extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapyDeLLphi-301
Thoracic Malignancies
Small-cell Lung Cancer
-
DeLLphi-301
2
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
2
Repotrectinib
-
Single arm
Repotrectinib used for locally advanced or metastatic ROS1-positive non-small cell lung cancer. FDA approval that includes patients with ROS1-positive NSCLC who have previously received a ROS1 tyrosine kinase inhibitor (TKI)TRIDENT-1
Thoracic Malignancies
Non-small-cell Lung Cancer
ROS1-positive (previously received TKI)
TRIDENT-1
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Atezolizumab
-
Single arm
For adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS).Study ML39345
Sarcoma
Alveolar soft part
-
Study ML39345
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Melphalan
-
Single arm
A liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiationFOCUS
Skin Cancers
Uveal melanoma
-
FOCUS
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Trastuzumab
-
Chemotherapy
Patients with HER2-positive early breast cancer following surgery, ChT (neoadjuvant or adjuvant) and RT (if applicable)HERA
As a single agent for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapyEMILIA
Breast Cancer
Breast Cancer
HER2+
EMILIA
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Pertuzumab
Trastuzumab + docetaxel
Trastuzumab + docetaxel + placebo
Treatment of patients with HER2-positive metastatic or locally recurrent unresectable BC who have not received previous anti-HER2 therapy or ChT for metastatic diseaseCLEOPATRA
Breast Cancer
Breast Cancer
HER2+
CLEOPATRA
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Lapatinib
Trastuzumab
Lapatinib
Treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with trastuzumab for patients with HR- metastatic disease that has progressed on prior trastuzumab therapy of therapies in combination with ChTEGF104900
Breast Cancer
Breast Cancer
HER2+ HR-
EGF104900
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Palbociclib
Fulvestrant
Fulvestrant + placebo
Patients with hormone receptor-positive, HER2-negative locally advanced or MBC who have received prior endocrine therapy (ET)PALOMA-3
Breast Cancer
Breast Cancer
HR+ HER2-
PALOMA-3
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Palbociclib
Letrozole
Letrozole + placebo
Treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitorPALOMA-2
Breast Cancer
Breast Cancer
HR+ HER2-
PALOMA-2
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Palbociclib
Letrozole
Letrozole
Treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor.PALOMA-1/TRIO-18
Breast Cancer
Breast Cancer
HR+ HER2-
PALOMA-1/TRIO-18
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Ribociclib
Letrozole
Letrozole + placebo
Treatment of women with hormone receptor-positive, HER2-negative locally advanced or MBC as initial endocrine-based therapy, or in women who have received prior ET MONALEESA-2
Breast Cancer
Breast Cancer
HR+ HER2-
MONALEESA-2
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Lapatinib
Capecitabine
Capecitabine
Treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic settingEGF100151
Breast Cancer
Breast Cancer
HER2+
EGF100151
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Bevacizumab
Paclitaxel
Paclitaxel
First-line treatment of adult patients with metastatic breast cancerE2100
Breast Cancer
Breast Cancer
-
E2100
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Everolimus
Exemestane
Exemestane + placebo
Treatment of HR+, HER2- advanced breast cancer, in combination with exemestane, in postmenpausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitorBOLERO-2
Breast Cancer
Breast Cancer
HR+ HER2-
BOLERO-2
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Eribulin
-
Treatment of physician's choice
As monotherapy for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after ≥1 ChT regimen for advanced diseaseEMBRACE
Breast Cancer
Breast Cancer
-
EMBRACE
2
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
2
Eribulin
-
Treatment of physician's choice
Treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatmentsStudy 305 & Study 301 (Pooled analysis)
Breast Cancer
Breast Cancer
HER2-
Study 305 & Study 301 (Pooled analysis)
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
1
Panitumumab
FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin)
FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin)
First-line treatment of patients with wild-type RAS mCRC PRIME
Treatment of patients with EGFR-expressing, RAS wild-type mCRC CRYSTAL
Gastrointestinal Cancers
Colorectal Cancer
EGFR-expressing RAS-WT
CRYSTAL
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Therapeutic Indication
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.